Combination of renal angioplasty and angiotensin-converting-enzyme inhibitor can reduce proteinuria in patients with bilateral renal artery disease

Research output: Contribution to journalArticle

Abstract

Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.

Original languageEnglish
Pages (from-to)1917-1922
Number of pages6
JournalInternal Medicine
Volume58
Issue number13
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Renal Artery
Angioplasty
Proteinuria
Angiotensin-Converting Enzyme Inhibitors
Kidney
Renal Artery Obstruction
Therapeutics
Clinical Trials

Keywords

  • Angioplasty
  • Angiotensin-converting-enzyme inhibitor
  • Proteinuria
  • Renal artery disease

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{f9c06933dc9f4810b497907732f61002,
title = "Combination of renal angioplasty and angiotensin-converting-enzyme inhibitor can reduce proteinuria in patients with bilateral renal artery disease",
abstract = "Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.",
keywords = "Angioplasty, Angiotensin-converting-enzyme inhibitor, Proteinuria, Renal artery disease",
author = "Hironobu Toda and Uchida, {Haruhito Adam} and Kazufumi Nakamura and Hidemi Takeuchi and Masaru Kinomura and Koji Nakagawa and Atsuyuki Watanabe and Toru Miyoshi and Nobuhiro Nishii and Hiroshi Morita and Jun Wada and Hiroshi Itoh",
year = "2019",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.2076-18",
language = "English",
volume = "58",
pages = "1917--1922",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "13",

}

TY - JOUR

T1 - Combination of renal angioplasty and angiotensin-converting-enzyme inhibitor can reduce proteinuria in patients with bilateral renal artery disease

AU - Toda, Hironobu

AU - Uchida, Haruhito Adam

AU - Nakamura, Kazufumi

AU - Takeuchi, Hidemi

AU - Kinomura, Masaru

AU - Nakagawa, Koji

AU - Watanabe, Atsuyuki

AU - Miyoshi, Toru

AU - Nishii, Nobuhiro

AU - Morita, Hiroshi

AU - Wada, Jun

AU - Itoh, Hiroshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.

AB - Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.

KW - Angioplasty

KW - Angiotensin-converting-enzyme inhibitor

KW - Proteinuria

KW - Renal artery disease

UR - http://www.scopus.com/inward/record.url?scp=85069163072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069163072&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.2076-18

DO - 10.2169/internalmedicine.2076-18

M3 - Article

C2 - 30799351

AN - SCOPUS:85069163072

VL - 58

SP - 1917

EP - 1922

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 13

ER -